(291 days)
Not Found
No
The description focuses on the physical mechanism of action (acoustic waves) and user-adjustable parameters, with no mention of AI or ML technologies.
Yes
The device is explicitly described as a "non-invasive therapeutic device" in the "Device Description" section, and its "Intended Use" clearly outlines therapeutic benefits such as pain relief and increased blood circulation.
No
The device description and intended use indicate that the BTL-094 is a therapeutic device designed to stimulate biological responses and provide pain relief, not to diagnose medical conditions.
No
The device description explicitly details hardware components such as a piezo transducer, applicator, main unit with a touch screen, and a secondary screen on the applicator, which are essential for its function.
Based on the provided information, the BTL-094 device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended uses listed are for therapeutic purposes (relief of muscle aches, increased blood circulation, connective tissue activation). These are treatments applied directly to the patient's body.
- Device Description: The description clearly states it's a "non-invasive therapeutic device" that uses acoustic waves to stimulate a biological response in the treated tissue. This describes a physical therapy device, not a device used to examine specimens from the body.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), performing tests on these samples, or providing diagnostic information based on such analysis.
IVD devices are used to examine specimens from the human body to provide information for diagnostic, monitoring, or compatibility purposes. The BTL-094 does not fit this description.
N/A
Intended Use / Indications for Use
BTL-094 is indicated to be used for:
- Relief of minor muscle aches and pains.
- Temporary increase in local blood circulation.
- Activation of connective tissue.
Product codes
ISA
Device Description
The BTL-094 is a non-invasive therapeutic device, which uses acoustic waves in order to stimulate a local biological response in the treated tissue.
The BTL-094 generates extracorporeally induced massage pulses to stimulate a local biological response in the treated tissue. The main source of acoustic waves is a piezo transducer inside the applicator. The energy transfer from the piezo transducer to the treated tissue is realized via coupling pad.
The main unit is equipped with a color touch screen, which considerably simplifies its operation. The onscreen information guides the user step through the entire therapy process. A secondary screen is placed on the applicator for the presentation of the actual state of main therapy parameters. The therapeutic parameters are adjustable via touch-screen, buttons and knob. The user is able to set following therapy parameters: intensity, frequency and number of shocks.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Non-clinical Testing:
The BTL-094 device has been thoroughly evaluated for electrical safety. The device has been found to comply with the following applicable medical device safety standards:
- IEC 60601-1:2005/A1:2012 Medical electrical equipment - Part 1: General requirements for basic safety and essential performance
- IEC 60601-1-2:2014 Medical electrical equipment – Part 1-2: General requirements for basic safety and essential performance - Collateral standard: Electromagnetic disturbances - Requirements and tests
- IEC 60601-1-6:2010/A1:2013 Medical electrical equipment - Part 1-6: General requirements for basic safety and essential performance - Collateral standard: Usability
- IEC 60601-2-36:2014 Medical electrical equipment - Part 2-36: Particular requirements for the basic safety and essential performance of equipment for extracorporeally induced lithotripsy
- IEC 62304:2006/A1:2015 Medical device software – Software lifecycle processes
- ISO 14971:2019 Medical devices - Application of risk management to medical devices
- ISO 10993-1:2018 Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process
- ISO 10993-5:2009 Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity
- ISO 10993-10:2010 Biological evaluation of medical devices – Part 10: Tests for irritation and skin sensitization
Clinical Testing:
Not applicable
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 890.5660 Therapeutic massager.
(a)
Identification. A therapeutic massager is an electrically powered device intended for medical purposes, such as to relieve minor muscle aches and pains.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 890.9.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health and Human Services logo on the left and the FDA logo on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.
April 14, 2023
BTL Industries Inc. David Chmel VP of Operations 362 Elm Street Marlborough, Massachusetts 01752
Re: K221865
Trade/Device Name: BTL-094 Regulation Number: 21 CFR 890.5660 Regulation Name: Therapeutic Massager Regulatory Class: Class I Product Code: ISA Dated: March 20, 2023 Received: March 20, 2023
Dear David Chmel:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
1
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Amber T. Ballard -S
Amber Ballard, PhD Assistant Director DHT5B: Division of Neuromodulation and Physical Medicine Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K221865
Device Name BTL-094
Indications for Use (Describe) BTL-094 is indicated to be used for:
- Relief of minor muscle aches and pains.
- Temporary increase in local blood circulation.
- Activation of connective tissue.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
X Prescription Use (Part 21 CFR 801 Subpart D)
| | Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the logo for BTL Industries. The logo consists of a blue geometric design on the left and the text "BTL Industries" on the right. The geometric design is made up of three squares, each nested inside the other.
510(k) Summary
General Information
| Sponsor: | BTL Industries, Inc.
362 Elm Street
Marlborough, MA 01752
Tel: +1-866-285-1656
Fax: +1-888-499-2502 |
|------------------------------|-----------------------------------------------------------------------------------------------------------------|
| Applicant: | BTL Industries, Inc.
362 Elm Street
Marlborough, MA 01752
Tel: +1-866-285-1656
Fax: +1-888-499-2502 |
| Contact Person: | David Chmel
BTL Industries, Inc.
chmel@btlnet.com |
| Summary Preparation
Date: | April 14, 2023 |
Device Name
| Trade/Proprietary Name: | BTL-094 |
|---|---|
| Primary Classification Name: | Therapeutic Massager |
| Common/Usual Name: | Therapeutic Massager |
| Classification Regulation: | 21 CFR 890.5660, Class I |
| Classification Product Code: | ISA |
4
Legally Marketed Predicate Device
The BTL-094 is a state-of-the-art device substantially equivalent to the following products, which are already cleared for distribution in the USA under the following 510(k) Premarket Notification number:
Product Description
The BTL-094 is a non-invasive therapeutic device, which uses acoustic waves in order to stimulate a local biological response in the treated tissue.
The BTL-094 generates extracorporeally induced massage pulses to stimulate a local biological response in the treated tissue. The main source of acoustic waves is a piezo transducer inside the applicator. The energy transfer from the piezo transducer to the treated tissue is realized via coupling pad.
The main unit is equipped with a color touch screen, which considerably simplifies its operation. The onscreen information guides the user step through the entire therapy process. A secondary screen is placed on the applicator for the presentation of the actual state of main therapy parameters. The therapeutic parameters are adjustable via touch-screen, buttons and knob. The user is able to set following therapy parameters: intensity, frequency and number of shocks.
The mechanism of action and technological similarities and differences between the BTL-094 device and the predicate devices are described below in the comparison table. The differences do not raise any new types of safety or effectiveness questions.
Indications For Use
BTL-094 is indicated to be used for:
- Relief of minor muscle aches and pains.
- Temporary increase in local blood circulation.
- Activation of connective tissue.
5
Image /page/5/Picture/0 description: The image shows the logo for BTL Industries. The logo consists of a blue geometric design on the left and the text "BTL Industries" on the right. The geometric design is made up of three squares, each containing the letters "B", "T", and "L" respectively.
Non-clinical Testing
The BTL-094 device has been thoroughly evaluated for electrical safety. The device has been found to comply with the following applicable medical device safety standards:
| IEC 60601-1:2005/A1:2012
FR Recognition Number: 19-4 | Medical electrical equipment - Part 1: General requirements for
basic safety and essential performance |
|-----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IEC 60601-1-2:2014
FR Recognition Number: 19-8 | Medical electrical equipment – Part 1-2: General requirements for
basic safety and essential performance - Collateral standard:
Electromagnetic disturbances - Requirements and tests |
| IEC 60601-1-6:2010/A1:2013
FR Recognition Number: 5-89 | Medical electrical equipment - Part 1-6: General requirements for
basic safety and essential performance - Collateral standard:
Usability |
| IEC 60601-2-36:2014
FR Recognition Number: 9-119 | Medical electrical equipment - Part 2-36: Particular requirements for
the basic safety and essential performance of equipment for
extracorporeally induced lithotripsy |
| IEC 62304:2006/A1:2015
FR Recognition Number: 13-79 | Medical device software – Software lifecycle processes |
| ISO 14971:2019
FR Recognition Number: 5-125 | Medical devices - Application of risk management to medical
devices |
| ISO 10993-1:2018
FR Recognition Number: 2-258 | Biological evaluation of medical devices – Part 1: Evaluation and
testing within a risk management process |
| ISO 10993-5:2009
FR Recognition Number: 2-245 | Biological evaluation of medical devices - Part 5: Tests for in vitro
cytotoxicity |
| ISO 10993-10:2010
FR Recognition Number: 2-174 | Biological evaluation of medical devices – Part 10: Tests for
irritation and skin sensitization |
Clinical Testing
Not aplicable
Technological Characteristics
The BTL-094 is a non-invasive therapeutic device, which uses acoustic waves in order to stimulate a local biological response in the treated tissue.
The BTL-094 generates extracorporeally induced massage pulses to stimulate a local biological response in the treated tissue. The main source of acoustic waves is a piezo transducer inside the applicator. The energy transfer from the piezo transducer to the treated tissue is realized via coupling pad.
6
The mechanism of action and technological similarities and differences between the BTL-094 device and the predicate devices are described below in the comparison table. The differences do not raise any new types of safety or effectiveness questions.
| Comparison with the Predicate Device | |||
|---|---|---|---|
| -------------------------------------- | -- | -- | -- |
| 510(k)
| number | K221865 | K173692 | K220538 | |
|---|---|---|---|---|
| Device name | BTL-094 | D-Actor 200 | DolorClast® | |
| Radial | ||||
| Company | ||||
| name | BTL Industries Inc. | Storz Medical | EMS Electro | |
| Medical SA | ||||
| Indications for | ||||
| Use | Relief of minor | |||
| muscle aches and | ||||
| pains | ||||
| Temporary increase | ||||
| in local blood | ||||
| circulation | ||||
| Activation of | ||||
| connective tissue | *Relief of minor | |||
| muscle aches and | ||||
| pains | ||||
| *Temporary increase | ||||
| in local blood | ||||
| circulation | ||||
| *Activation of | ||||
| connective tissue | - Relief of minor | |||
| muscle aches and | ||||
| pains. |
- Temporary
increase in local
blood circulation. - Activation of
connective tissue. | None |
| Product Code
and
Regulation | 21 CFR
890.5660
ISA | 21 CFR
890.5660
ISA | 21 CFR
890.5660
ISA | None |
| Modes of
Action | Extracorporeally
induced pressure
waves. | Radial pressure
waves, or
extracorporeal pulse
activation
respectively | Radial pressure
waves, or
extracorporeal
pulse activation
respectively | Not Significantly
different
Please see the
discussion and
conclusion below. |
| Mechanisms of
Action | Vibrations generated
by electroacoustic
technology. | Pneumatically
generated vibrations | Pneumatically
generated
vibrations | Not Significantly
different
Please see the
discussion and
conclusion below. |
| Maximum and
Minimum
intensity
settings | 5-30%
alternative output
power setting scale | 1-5bar | 1-4bar | Not Significantly
different
Differences are
caused by
alternative
technology of the
pressure wave
generation. |
| Number and
size of
treatment
applicator
heads | 2;
L Pad - 12.2 cm²
U Pad - 7.3 cm² | 4;
6mmOD, 15mmOD,
20mmOD, 35mmOD | 7;
5mm OD, 10 mm
OD, 15 mm OD, 25
mm OD, 40 mm OD | Not Significantly
different
The application
area of the pads in
contact with the
patient is within the
set range of the
predicate devices.
All materials in
contact with the
patient have been
assessed for
biocompatibility |
| Maximum and
minimum
displacements
of applicator
heads | N/A | 0.6 - 2.0mm | 0.18 - 0.28 mm | N/A
The BTL-094
applicator does not
have any moving
parts that come in
contact with the
patient. |
| Type of
application
(e.g.,
continuous
vibration at a
fixed
frequency); | Continuous vibration
at a fixed frequency
and single pulse
mode | Continuous vibration
at a fixed frequency | Continuous
vibration at a fixed
frequency | None |
| Maximum and
minimum
vibration
frequency | 1-25 Hz | 1-21Hz | 1-25 Hz | Not Significantly
different |
| Power Supply | 100 V to 240 V AC
50 - 60 Hz
150VA | 500VA | Mains power | None |
| Maximum
penetration
depth | 35 mm | 32.3mm | 40 mm | Not Significantly
different
Please see the
discussion and
conclusion below. |
| Energy flow
density | In the range of
0.01 - 0.11 mJ/mm2 | Values of ultrasonic
pulse:
5bar/0.284mJ/mm2
3bar/0.176mJ/mm2 | 0.29 mJ/mm2 at 4
bar
0.14 mJ/mm2 at 2.4
bar | Not Significantly
different |
| Operating
mode | Continuous | Continuous | Continuous | None |
| Projectile
mass (g) | N/A | 3 | 3.2 | Not applicable
The BTL-094
applicator does not
contain a projectile. |
| Pulse repeat
rate (1/s) | 1-25 Hz | 1-21Hz | 1-25 Hz | Not Significantly
different |
| Number of
pulses (min
and max) | Variable in range
0 – 9999 | Variable | Variable,
Max
5000/treatment | Not Significantly
different |
| Maximum
operating
temperature | 10 - 35 °C | 10-40°C | 10 - 30 °C | Not Significantly
different |
| Type of
acoustic wave
generation | Electroacoustic
technology with
electroacoustic lens
system | Pneumatic/ballistic | Pneumatic/ballistic | Not Significantly
different
Differences are
caused by
alternative
technology of the
pressure wave
generation. |
| Positive peak
pressure
amplitude
(MPa) | In the range of
3 - 10 MPa | Values of ultrasonic
pulse: 5bar/18.5MPa
3bar/13.4MPa | 17 MPa at 4 bar
11.24 MPa at 2.4
bar | Not Significantly
different
Please see the
discussion and
conclusion below. |
| Negative peak
pressure
amplitude
(MPa) | In the range of
3 - 10 MPa | Values of ultrasonic
pulse: 5bar/6.8MPa
3bar/5.0MPa | 10 MPa at 4 bar
7.2 MPa at 2.4 bar | Not Significantly
different
Please see the
discussion and
conclusion below. |
| Derived focal
acoustic pulse
energy (mJ) | In the range of
0.1 – 1.4 mJ | Values of ultrasonic
pulse: 5bar/6.5mJ
3bar/2.4mJ | 5.9 mJ at 4 bar*
2.2 mJ at 2.4 bar*
*Averaged across
all applicator sizes. | Not Significantly
different
Please see the
discussion and
conclusion below. |
| Derived
pulse-
intensity
integral,
integrated over
total temporal
integration
limits
(mJ/mm2) | In the range of
0.01 - 0.11 mJ/mm2 | Values of ultrasonic
pulse:
5bar/0.284mJ/mm2
3bar/0.176mJ/mm2 | 0.29 mJ/mm2 at 4
bar
0.14 mJ/mm2 at 2.4
bar | Not Significantly
different
Please see the
discussion and
conclusion below. |
| Rise time (ns) | 10 ns | Ultrasonic pulse:
2.5µs | 3.2 µs | Not Significantly
different |
| | | Sonic pulse: 25µs –
2.5ms | | Differences are
caused by
alternative
technology of the
energy generation. |
| Compressional
pulse duration
(μs) | 2µs | Ultrasonic pulse:
5.0µs Sonic pulse:
50µs – 5.0ms | 2.6 µs (1st peak)
62.7 µs (1st phase) | Not Significantly
different |
7
Image /page/7/Picture/0 description: The image shows the logo for BTL Industries. The logo consists of three interconnected blue squares with the letters "BTL" inside. To the right of the logo, the words "BTL Industries" are written in a modern, sans-serif font. The text is in a dark gray color.
8
Image /page/8/Picture/0 description: The image shows the logo for BTL Industries. The logo consists of three nested squares with the letters "BTL" inside the innermost square. To the right of the logo is the text "BTL Industries" in a sans-serif font.
9
Image /page/9/Picture/0 description: The image shows the logo for BTL Industries. The logo consists of three blue squares nested inside each other, with the letters "BTL" in white inside the innermost square. To the right of the square logo is the text "BTL Industries" in a gray sans-serif font.
Modes of Action, Mechanisms of Action
The technology used in BTL-094 device differs from the predicate device. Nevertheless, the technology creates the same type of acoustic pressure delivered to the tissue. Similar devices that generate a pressure wave based on a different technological principle but with the same or very comparable mechanism of action have already been recognised as substantially equivalent in this device category.
Maximum and Minimum intensity settings
BTL-094 has an alternative type of technology from the predicate device and therefore the BTL-094 device has an alternative power setting scale - in percentage and not in bars as a comparative device has. In addition, for comparability with the predicate devices the BTL-094 device intended for the US market is limited to a maximum power level of 30% of maximum driving power.
Number and size of treatment applicator heads
The number of application pads are different from predicate device but the area of the subjected device pads that is in contact with the patient is comparable within a set range to the contact area of application tips of predicate devices. Additionally all materials in contact with patient have been assessed for biocompatibility and the maximal depth of pressure wave penetration is comparable to the predicate.
Maximum and minimum displacements of applicator heads
The predicate device is generating the pressure wave by the head displacement. Due to an alternative type of technology used for pressure wave generation the BTL-094 device does not have the ability of displacements of applicator heads/pads.
Maximum and minimum vibration frequency
BTL-094 device differs from one predicate device in the value of the maximum frequency, where the frequency value of the BTL-094 device can be up to 4Hz higher than the predicate device, but has available the same frequency range as its second predicate device.
Driving Power
BTL-094 device has an alternative type of technology from the predicate device and therefore the driving power parameter is not applicable. In addition, for comparability with the predicate devices the BTL-094 device intended for the US market is limited to a maximum power level of 30% of maximum driving power.
Energy flow density
BTL-094 device uses alternative technology and is able to better pulse targeting, a maximum driving power of the device has been limited at a maximum power level of 30%. The EFD of our device differs from the predicates but it is lower or within setting range of predicat devices.
10
Image /page/10/Picture/0 description: The image shows the logo for BTL Industries. The logo consists of a geometric design on the left and the text "BTL Industries" on the right. The geometric design is made up of three squares, each rotated 45 degrees and nested inside the other. The text "BTL Industries" is written in a sans-serif font.
Operating mode
The BTL-094 device has two modes of operation: single therapy mode or sequence mode. The two modes differ based on repetition of therapy sections and settings that can be done during the running therapy. Nevertheless, both the modes have a character of continual therapy.
Maximum penetration depth
The BTL-094 device is equipped with two different coupling pad sizes, which allow it to reach up to 35 mm depth. This penetration depth is comparable within setting range of predicate devices.
Pulse repeat rate (1/s)
BTL-094 device differs from one predicate device in the value of the maximum frequency, where the frequency value of the BTL-094 device can be up to 4Hz higher than the predicate device, but has available the same frequency range as its second predicate device.
Number of pulses (min and max)
BTL-094 device allows to set a variable number of pulses according to the user's needs. This parameter is similar as for the predicate device.
Type of acoustic wave generation
The subject device provides the therapy by the application of extracorporeally induced acoustic pressure waves that are generated by means of piezoelectric principle. The device is designed with planar piezoelement and acoustic lens quiding the waves. The generated wave is coupled to biological tissue via the coupling gel pads of the applicator.
This technology creates the same type of acoustic pressure wave with comparable parameters therefore it reach the same mechanism of action as the predicate devices.
Positive peak pressure amplitude (MPa)
A maximum driving power of the BTL-094 has been limited at a maximum power level of 30%. The device with this limitation in maximal output power fits with output parameters within or bellow setting range of predicat devices and is not significantly different from the predicate devices.
Negative peak pressure amplitude (MPa)
A maximum driving power of the BTL-094 has been limited at a maximum power level of 30%. The device with this limitation in maximal output power fits with output parameters within or bellow setting range of predicat devices and is not significantly different from the predicate devices.
Derived focal acoustic pulse energy (mJ)
A maximum driving power of the BTL-094 has been limited at a maximum power level of 30%. The device with this limitation in maximal output power fits with output parameters within or bellow setting range of predicat devices and is not significantly different from the predicate devices.
Derived pulse- intensity integrated over total temporal integration limits (m.J/mm2)
A maximum driving power of the BTL-094 has been limited at a maximum power level of 30%. The device with this limitation in maximal output power parameters within or bellow setting range of predicat devices and is not significantly different from the predicate devices.
Rise time (ns)
BTL-094 has an alternative type of technology from the predicate device and therefore the BTL-094 device is able to reach a faster rise time and shorter compressional pulse duration.
11
Image /page/11/Picture/0 description: The image shows the logo for BTL Industries. The logo consists of three blue interlocking squares on the left, with the letters "BTL" inside the squares. To the right of the squares is the text "BTL Industries" in a gray sans-serif font. The logo is simple and modern, and the use of blue and gray gives it a professional look.
Compressional pulse duration (µs)
BTL-094 has an alternative type of technology from the predicate device and therefore the BTL-094 device is able to reach a faster rise time and shorter compressional pulse duration.
Substantial Equivalence
The BTL-094 is substantially equivalent to the predicate devices D-Actor (K173692) and DolorClast® Radial (K220538). The subject device is safe and effective for its intended use.
Any differences between the predicate devices and BTL-094 have no significant influence on the safety or effectiveness of the subject device. Therefore, the BTL-094 is substantially equivalent to the predicate devices.
Conclusion
Based upon the intended use and known technical information provided in this pre-market notification, the BTL-094 device has been shown to be substantially equivalent to the currently marketed predicate device.